Flapan A D
Department of Cardiology, Royal Infirmary of Edinburgh.
BMJ. 1994 Oct 29;309(6962):1129-34. doi: 10.1136/bmj.309.6962.1129.
In the past 20 years there has been a steady improvement in the short term prognosis of patients with myocardial infarction, following the introduction of beta blockers, thrombolysis, and aspirin. Patients treated with thrombolytic drugs have a lower overall mortality after myocardial infarction but remain at risk of non-fatal reinfarction or death, and in one study almost half of all survivors of acute myocardial infarction died or suffered a further ischaemic event within three years. It is therefore important to have a strategy to identify patients at high risk, to reduce the subsequent development of cardiac failure and mortality, and to have effective measures for secondary prevention to reduce the incidence of reinfarction as well as to promote rehabilitation.
在过去20年里,随着β受体阻滞剂、溶栓治疗及阿司匹林的应用,心肌梗死患者的短期预后有了稳步改善。接受溶栓药物治疗的患者心肌梗死后的总体死亡率较低,但仍有非致命性再梗死或死亡的风险,并且在一项研究中,几乎一半的急性心肌梗死幸存者在三年内死亡或再次发生缺血性事件。因此,制定一项策略来识别高危患者、降低随后心力衰竭的发生及死亡率、采取有效的二级预防措施以降低再梗死发生率并促进康复非常重要。